Grunenthal GmbH - Company Profile
Powered by 
All the sales intelligence you need on Grunenthal GmbH in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Grunenthal GmbH fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Grunenthal GmbH.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company that researches, develops and markets products for the treatment of pain management and related diseases. Its portfolio includes a wide range of medicinal products for chronic and acute pain, nociceptive and neuropathic pain. The company’s product portfolio includes Tramal, used for the treatment of moderate to severe pain; Transtec, used to treat moderate to severe cancer pain; and Vimovo, used for the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. The company distributes products and operates in Europe, Latin America and the US. Grunenthal is headquartered in Aachen, Nordrhein-Westfalen, Germany.
Headquarters
Germany
Address
Zieglerstrasse 6, Aachen, Nordrhein-Westfalen, 52078
Website
www.grunenthal.com
Telephone
49 241 5690
No of Employees
4,300
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$2.0B
Grunenthal GmbH premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Versatis - for Neuropathic Pain | Nexium |
| Qutenza - for Peripheral Neuropathic Pain in Adults | Versatis |
| Transtec - for Moderate to Severe Cancer Pain | Tramal |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In June, the company acquired the commercial rights to Cialis (tadalafil) in Mexico, Brazil and Colombia from Eli Lilly and Co. |
| 2024 | Acquisitions/Mergers/Takeovers | In July, the company acquired Valinor Pharma, a pharmaceutical company, for US$250 million. |
| 2023 | Contracts/Agreements | In August, the company and Kyowa Kirin Co Ltd formed a joint venture collaboration for Kyowa Kirin International's established medicines portfolio. |
Competitor Comparison
| Key Parameters | Grunenthal GmbH | Mibe GmbH Arzneimittel | TAD Pharma GmbH | Mundipharma International Ltd | Endo Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | Germany | Germany | Germany | United Kingdom | United States of America |
| City | Aachen | Brehna | Cuxhaven | Cambridge | Chester |
| State/Province | Nordrhein-Westfalen | Sachsen-Anhalt | Niedersachsen | England | Pennsylvania |
| No. of Employees | 4,300 | 467 | 187 | 67 | - |
| Entity Type | Private | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gabriel Baertschi | Chief Executive Officer | Senior Management | 2016 | 52 |
| Fabian Raschke | Chief Financial Officer | Senior Management | 2019 | 49 |
| Uli Brodl, M.D. | Chief Scientific Officer | Senior Management | 2025 | 54 |
| Jan Adams, MD | Chief Commercial Officer | Senior Management | 2024 | 49 |
| Par Johansson | Chairman | Non Executive Board | - | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer